Cargando…
Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance
Background The majority of adverse drug reactions (ADRs) reported in the summary of product characteristics (SPCs) are based on pivotal clinical trials, performed under controlled conditions and with selected patients. Objectives (1) to observe ADRs in the real-world setting and to evaluate if the s...
Autores principales: | Fornasier, G., Taborelli, M., Francescon, S., Polesel, J., Aliberti, M., De Paoli, P., Baldo, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132980/ https://www.ncbi.nlm.nih.gov/pubmed/29785683 http://dx.doi.org/10.1007/s11096-018-0653-5 |
Ejemplares similares
-
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016) -
Pharmacovigilance in oncology
por: Baldo, Paolo, et al.
Publicado: (2018) -
Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology
por: Baldo, Paolo, et al.
Publicado: (2018) -
An historical overview over Pharmacovigilance
por: Fornasier, Giulia, et al.
Publicado: (2018) -
EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)